Shots:

• The approval is based on the study assessing of Absorica vs another isotretinoin 925 patients aged 12 years and older in patients with severe recalcitrant nodular acne
• Study results: Mean reduction in nodular lesions (-15.68 vs -15.62); 90% reduction in total nodular lesion count (70% vs 75%)
• Absorica ((isotretinoin) is a prescription medicine granted patients aged 12 years of age and older treat the most severe form of acne nodular acne and also have a boxed warning for embryo-fetal toxicity – contraindicated in pregnancy

Click here to­ read full press release/ article | Ref: Optumrx | Image: Twitter